Psyence Biomedical Ltd. Files 6-K Report
Ticker: PBMWW · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1985062
Sentiment: neutral
Topics: reporting, 6-K
TL;DR
Psyence Biomedical filed a 6-K, standard reporting. CEO Neil Maresky signed off.
AI Summary
Psyence Biomedical Ltd. filed a Form 6-K on December 23, 2024, reporting for the month of December 2024. The filing includes a press release as Exhibit 99.1. Dr. Neil Maresky, CEO and Director, signed the report on behalf of the company.
Why It Matters
This filing indicates ongoing reporting activity for Psyence Biomedical Ltd., which is standard for publicly traded companies and provides updates to investors.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other periodic information, not significant new financial events.
Key Players & Entities
- Psyence Biomedical Ltd. (company) — Registrant
- Neil Maresky (person) — Chief Executive Officer and Director
- December 23, 2024 (date) — Filing Date
FAQ
What type of report is Psyence Biomedical Ltd. filing?
Psyence Biomedical Ltd. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
What is the filing date of this report?
The filing date of this report is December 23, 2024.
Who signed the report on behalf of Psyence Biomedical Ltd.?
Dr. Neil Maresky, Chief Executive Officer and Director, signed the report.
What is included as an exhibit in this filing?
Exhibit 99.1, a Press Release, is included in this filing.
What is the principal executive office address for Psyence Biomedical Ltd.?
The principal executive office is located at 121 Richmond Street West Penthouse Suite 1300, Toronto, Ontario M5H 2K1.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-12-23 17:29:58
Filing Documents
- tm2431883d1_6k.htm (6-K) — 10KB
- tm2431883d1_ex99-1.htm (EX-99.1) — 13KB
- 0001104659-24-131392.txt ( ) — 24KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-41937 Psyence Biomedical Ltd. (Translation of registrant’s name into English) 121 Richmond Street West Penthouse Suite 1300 Toronto, Ontario M5H 2K1 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBIT INDEX EXHIBIT INDEX Exhibit Description 99.1 Press Release SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 23, 2024 Psyence Biomedical Ltd. By: /s/ Neil Maresky Name: Dr. Neil Maresky Title: Chief Executive Officer and Director